NTRA Natera Inc
Company Analysis
Latest News
Natera Signatera predicts lung cancer recurrence, citing largest-ever MRD study results
Natera presented new data for its Signatera molecular residual disease (MRD) test at the IASLC 2026 World Conference on Lung Cancer. The study analyzed over...
Natera Chairman Sells $35M in Stock Following 97% Annual Rally
Natera Executive Chairman Matthew Rabinowitz sold 101,000 shares of company stock on September 14 and 15. The total value of the transactions reached...
🟢 Natera rises 4.0% — Biotech Sector Rallies on Strong Industry Outlook and M&A Optimism
With Biotech (XBI) up 2.5%, this looks like a sector-led move rather than a company-specific surprise. The biotechnology sector, as measured by the XBI ETF,...
🟢 Natera is trading 4.14% up today
Natera is trading at $342.54, up +4.14% on September 14, 2026, outperforming the broader market as major indexes are lower. - Management presented growth...
Natera initiated at Buy with $435 target, citing MRD market leadership
UBS initiated coverage on Natera with a Buy rating. The bank established a price target of $435 for the stock. Analysts identified Natera as a leader in the...
🟢 Natera is trading 4.5% up in pre-market; no confirmed company-specific catalyst identified
Natera is trading 4.52% up at $343.00, with no confirmed company-specific announcement identified for September 8, 2026. - The latest notable company news was...
Natera Validates Signatera for Lymphoma, Outperforming Standard PET/CT Scans
Natera published data in the journal Blood Neoplasia validating its Signatera molecular residual disease (MRD) test for lymphoma. The study evaluated 144...
Viking Global Takes New $106M Position in Diagnostics Firm Natera
Andreas Halvorsen's Viking Global Investors initiated a significant new stake in Natera Inc., a genetic testing and diagnostics company. The investment, valued...
Farallon Capital Opens Major New $641M Position in Natera (NTRA)
In a recent disclosure, Farallon Capital Management reported establishing a significant new stake in Natera, Inc. (NTRA), a leader in cell-free DNA (cfDNA)...
🟢 Natera is trading 4.78% up in pre-market with no clear company-specific catalyst identified
Natera is trading 4.78% up at $343.40, with no clear August 25, 2026 company-specific catalyst identified. - Latest major company news was August 6, 2026...
🟢 Natera is trading 6% up in pre-market after raised full-year guidance
Natera is trading 5.64% up at $343.15, with the move appearing consistent with continued investor momentum following its August 6 earnings report and raised...
🟢 Natera rises 4.2% — Biotech Sector Surges on Positive mRNA Cancer Vaccine Trial Results
With Biotech (XBI) up 3.7%, this looks like a sector-led move rather than a company-specific surprise. The biotech sector, proxied by the XBI ETF, is trading...
BlackRock Bets $2.96 Billion on Natera, Following Strong Earnings Beat
BlackRock Inc. acquired more than 10.9 million shares of Natera during the second quarter. The stake is valued at approximately $2.96 billion. This investment...
🟢 Natera is trading 4.5% up in pre-market — no fresh company-specific catalyst identified
Natera is trading 4.5% up in pre-market at $325.78 after no fresh company-specific catalyst was identified for August 19, 2026. - Its latest major company...
🔴 Natera is trading 5% down in pre-market as Nasdaq Composite fell 1.18%
Natera is trading 4.94% down now at $298.68 after broader risk-off sentiment pushed futures lower. - The Nasdaq Composite is down 1.18%, while the S&P 500 is...
T. Rowe Price Builds Natera Stake, Following Strong Q2 Results
T. Rowe Price Associates, Inc. disclosed a significant ownership stake in Natera Inc. on August 14, 2026. The firm filed a Schedule 13G indicating the shares...
🔴 Natera is trading 15.91% down today in after-hours trading with no reliable company-specific explanation identified
Natera is trading 15.91% down at $265.69 after-hours on August 12, 2026, with no reliable company-specific explanation identified for the decline. - Natera...
🟢 Natera is trading 8% up in pre-market after earnings beat and raised 2026 guidance
Natera is trading 7.95% up at $337.59 after continued investor response to August 6 earnings showing $752.8 million in revenue, record test volumes, and raised...
🔴 Natera is trading 13.85% down in after-hours trading with no verified company-specific announcement
Natera is trading 13.85% down at $274.25 in after-hours trading, with no verified company-specific announcement emerging on August 10, 2026. - Its latest...
Natera Smashes Q2 Estimates and Lifts Guidance, but Can a Still-Unprofitable Testing Company Justify a $39 Billion Valuation?
Shares of genetic testing company Natera surged 15.3% to $306.01, blasting past the stock's prior 52-week high, after the company delivered a second quarter...